Many effective drugs that are already developed will not reach patients for years because the clinical trial system is the primary bottleneck. This delay is due to logistical and structural inefficiencies in testing, not a lack of scientific discovery.

A major bottleneck in healthcare is the 17-20 year delay for scientific findings to become common practice. Dr. Christianson argues AI's immediate value is not just in moonshot cures, but in quickly productizing validated, non-prescription self-care knowledge (like vitamin D's impact) and delivering it to consumers.

The lengthy timelines of drug development create a significant perception lag for AI's impact. Molly Gibson clarifies that molecules currently in clinical trials were designed years ago using nascent AI models. The true capabilities of today's more advanced AI platforms won't be evident in approved drugs for several more years.

By analyzing millions of queries from clinicians, Open Evidence identifies high-frequency topics. It then cross-references these with its literature database to pinpoint areas that are both clinically relevant and poorly supported by existing evidence, effectively mapping the frontier of medical knowledge and research opportunities.

Singhal says asking five physicians one question can yield eight answers, so OpenAI built a network of hundreds of experts across specialties, languages, and countries. That network shapes evaluations and training data instead of letting one or two clinicians adjudicate hard cases. It is a deliberate aggregation of expert judgment.

An effective AI strategy in healthcare is not limited to consumer-facing assistants. A critical focus is building tools to augment the clinicians themselves. An AI 'assistant' for doctors to surface information and guide decisions scales expertise and improves care quality from the inside out.

The technical and data preparation for an AI-driven healthcare world will take pharma companies 18-24 months. If they wait until AI tools are mainstream, they will face an insurmountable two-year gap to catch up, a period in which they will become irrelevant.

The platform uses machine learning to combat the rapid obsolescence of medical guidelines. It systematically reviews every paragraph of ingested guidelines against new publications weekly, identifying and flagging specific sections that may be deprecated by more recent evidence, a critical function in fields like oncology.

Singhal says EHR histories, claims, and other stored healthcare data hold insights that are not fully mined. He sees agents helping generate new knowledge from that data and accelerating validation, which may become the key bottleneck in medical research. Scientists are a third core constituency.